Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques

• The Delta inactivated vaccine constructed in this study has high immunogenicity and good safety. • The inactivated vaccine has good cross-protection against SARS-CoV-2 variants. • The vaccine exhibited high productivity and good genetic stability in production.

Detalles Bibliográficos
Autores principales: Zhang, Yanjun, Mao, Haiyan, Li, Ju, Li, Jianhua, Huang, Chen, Li, Jiaxuan, Chu, Minglei, Xue, Fengbo, Wang, Linhui, Fang, Zhongbiao, Wang, Zhen, Wu, Jinan, Chen, Keda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212592/
https://www.ncbi.nlm.nih.gov/pubmed/37244519
http://dx.doi.org/10.1016/j.virs.2023.05.009
Descripción
Sumario:• The Delta inactivated vaccine constructed in this study has high immunogenicity and good safety. • The inactivated vaccine has good cross-protection against SARS-CoV-2 variants. • The vaccine exhibited high productivity and good genetic stability in production.

Ejemplares similares